GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 inhibitor medication had a lower risk of a subsequent stroke, heart attack or death ...

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 ...

MONDAY, Nov. 11, 2024 (HealthDay News) -- The weight-loss drug Ozempic can help reduce stroke patients’ risk of a heart ...

Stroke was the fourth leading cause of death in the US last year, accounting for 162,600 deaths, according to preliminary data.

On the question of whether the benefits of sotagliflozin, an oral dual sodium-glucose co-transporter types 1 and 2 (SGLT1/SGLT2) inhibitor, outweigh the risks in this patient population, the committee ...

Greatest increase in SGLT2 inhibitor use seen in subgroups with cardiovascular disease; greatest increase in GLP-1 RA for those with obesity ...

A recent case report highlights the importance of understanding the possibility of the development of Euglycemic diabetic ...

The medications include GLP-1 drugs such as Ozempic from Novo Nordisk and Trulicity from Eli Lilly, and SGLT2 drugs such as ...

SGLT2 inhibitors are a new family of agents, which occlude the path of SGLT2 glucose reabsorption and cause glucosuria. Efficacy of SGLT2 inhibitors includes reduction of HbA1c, fasting and ...